Cargando…

Impact of Sarcopenia and Myosteatosis in Non-Cirrhotic Stages of Liver Diseases: Similarities and Differences across Aetiologies and Possible Therapeutic Strategies

Sarcopenia is defined as a loss of muscle strength, mass and function and it is a predictor of mortality. Sarcopenia is not only a geriatric disease, but it is related to several chronic conditions, including liver diseases in both its early and advanced stages. Despite the increasing number of stud...

Descripción completa

Detalles Bibliográficos
Autores principales: Cespiati, Annalisa, Meroni, Marica, Lombardi, Rosa, Oberti, Giovanna, Dongiovanni, Paola, Fracanzani, Anna Ludovica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8773740/
https://www.ncbi.nlm.nih.gov/pubmed/35052859
http://dx.doi.org/10.3390/biomedicines10010182
_version_ 1784636169247522816
author Cespiati, Annalisa
Meroni, Marica
Lombardi, Rosa
Oberti, Giovanna
Dongiovanni, Paola
Fracanzani, Anna Ludovica
author_facet Cespiati, Annalisa
Meroni, Marica
Lombardi, Rosa
Oberti, Giovanna
Dongiovanni, Paola
Fracanzani, Anna Ludovica
author_sort Cespiati, Annalisa
collection PubMed
description Sarcopenia is defined as a loss of muscle strength, mass and function and it is a predictor of mortality. Sarcopenia is not only a geriatric disease, but it is related to several chronic conditions, including liver diseases in both its early and advanced stages. Despite the increasing number of studies exploring the role of sarcopenia in the early stages of chronic liver disease (CLD), its prevalence and the relationship between these two clinical entities are still controversial. Myosteatosis is characterized by fat accumulation in the muscles and it is related to advanced liver disease, although its role in the early stages is still under researched. Therefore, in this narrative review, we firstly aimed to evaluate the prevalence and the pathogenetic mechanisms underlying sarcopenia and myosteatosis in the early stage of CLD across different aetiologies (mainly non-alcoholic fatty liver disease, alcohol-related liver disease and viral hepatitis). Secondly, due to the increasing prevalence of sarcopenia worldwide, we aimed to revise the current and the future therapeutic approaches for the management of sarcopenia in CLD.
format Online
Article
Text
id pubmed-8773740
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87737402022-01-21 Impact of Sarcopenia and Myosteatosis in Non-Cirrhotic Stages of Liver Diseases: Similarities and Differences across Aetiologies and Possible Therapeutic Strategies Cespiati, Annalisa Meroni, Marica Lombardi, Rosa Oberti, Giovanna Dongiovanni, Paola Fracanzani, Anna Ludovica Biomedicines Review Sarcopenia is defined as a loss of muscle strength, mass and function and it is a predictor of mortality. Sarcopenia is not only a geriatric disease, but it is related to several chronic conditions, including liver diseases in both its early and advanced stages. Despite the increasing number of studies exploring the role of sarcopenia in the early stages of chronic liver disease (CLD), its prevalence and the relationship between these two clinical entities are still controversial. Myosteatosis is characterized by fat accumulation in the muscles and it is related to advanced liver disease, although its role in the early stages is still under researched. Therefore, in this narrative review, we firstly aimed to evaluate the prevalence and the pathogenetic mechanisms underlying sarcopenia and myosteatosis in the early stage of CLD across different aetiologies (mainly non-alcoholic fatty liver disease, alcohol-related liver disease and viral hepatitis). Secondly, due to the increasing prevalence of sarcopenia worldwide, we aimed to revise the current and the future therapeutic approaches for the management of sarcopenia in CLD. MDPI 2022-01-16 /pmc/articles/PMC8773740/ /pubmed/35052859 http://dx.doi.org/10.3390/biomedicines10010182 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Cespiati, Annalisa
Meroni, Marica
Lombardi, Rosa
Oberti, Giovanna
Dongiovanni, Paola
Fracanzani, Anna Ludovica
Impact of Sarcopenia and Myosteatosis in Non-Cirrhotic Stages of Liver Diseases: Similarities and Differences across Aetiologies and Possible Therapeutic Strategies
title Impact of Sarcopenia and Myosteatosis in Non-Cirrhotic Stages of Liver Diseases: Similarities and Differences across Aetiologies and Possible Therapeutic Strategies
title_full Impact of Sarcopenia and Myosteatosis in Non-Cirrhotic Stages of Liver Diseases: Similarities and Differences across Aetiologies and Possible Therapeutic Strategies
title_fullStr Impact of Sarcopenia and Myosteatosis in Non-Cirrhotic Stages of Liver Diseases: Similarities and Differences across Aetiologies and Possible Therapeutic Strategies
title_full_unstemmed Impact of Sarcopenia and Myosteatosis in Non-Cirrhotic Stages of Liver Diseases: Similarities and Differences across Aetiologies and Possible Therapeutic Strategies
title_short Impact of Sarcopenia and Myosteatosis in Non-Cirrhotic Stages of Liver Diseases: Similarities and Differences across Aetiologies and Possible Therapeutic Strategies
title_sort impact of sarcopenia and myosteatosis in non-cirrhotic stages of liver diseases: similarities and differences across aetiologies and possible therapeutic strategies
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8773740/
https://www.ncbi.nlm.nih.gov/pubmed/35052859
http://dx.doi.org/10.3390/biomedicines10010182
work_keys_str_mv AT cespiatiannalisa impactofsarcopeniaandmyosteatosisinnoncirrhoticstagesofliverdiseasessimilaritiesanddifferencesacrossaetiologiesandpossibletherapeuticstrategies
AT meronimarica impactofsarcopeniaandmyosteatosisinnoncirrhoticstagesofliverdiseasessimilaritiesanddifferencesacrossaetiologiesandpossibletherapeuticstrategies
AT lombardirosa impactofsarcopeniaandmyosteatosisinnoncirrhoticstagesofliverdiseasessimilaritiesanddifferencesacrossaetiologiesandpossibletherapeuticstrategies
AT obertigiovanna impactofsarcopeniaandmyosteatosisinnoncirrhoticstagesofliverdiseasessimilaritiesanddifferencesacrossaetiologiesandpossibletherapeuticstrategies
AT dongiovannipaola impactofsarcopeniaandmyosteatosisinnoncirrhoticstagesofliverdiseasessimilaritiesanddifferencesacrossaetiologiesandpossibletherapeuticstrategies
AT fracanzaniannaludovica impactofsarcopeniaandmyosteatosisinnoncirrhoticstagesofliverdiseasessimilaritiesanddifferencesacrossaetiologiesandpossibletherapeuticstrategies